Sebastian J. Schober

Jena, TH, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Specific and Multi-Product Clade I and Clade IV Sesquiterpene Synthases Contribute to the Psilocybe cubensis Volatilome.

Specific and Multi-Product Clade I and Clade IV Sesquiterpene Synthases Contribute to the Psilocybe cubensis Volatilome.

Journal: Chembiochem : a European journal of chemical biology
Published: February 10, 2026

Clade III Synthases Add Cyclic and Linear Terpenoids to the Psilocybe Metabolome.

Clade III Synthases Add Cyclic and Linear Terpenoids to the Psilocybe Metabolome.

Journal: Chembiochem : a European journal of chemical biology
Published: February 25, 2025

Linear magnetic nanoparticle structures as key feature in magnetic particle imaging.

Linear magnetic nanoparticle structures as key feature in magnetic particle imaging.

Journal: Physics in medicine and biology
Published: February 11, 2025

Cytokine screening identifies TNF to potentially enhance immunogenicity of pediatric sarcomas.

Cytokine screening identifies TNF to potentially enhance immunogenicity of pediatric sarcomas.

Journal: Frontiers in immunology
Published: November 30, 2023

TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model.

TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model.

Journal: Frontiers in immunology
Published: October 31, 2023

YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells.

YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells.

Journal: Frontiers in oncology
Published: September 29, 2023

The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma.

The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 12, 2022

No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care Therapy.

No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care Therapy.

Journal: Frontiers in oncology
Published: February 17, 2022

Monocyte Maturation Mediators Upregulate CD83, ICAM-1 and MHC Class 1 Expression on Ewing's Sarcoma, Enhancing T Cell Cytotoxicity.

Monocyte Maturation Mediators Upregulate CD83, ICAM-1 and MHC Class 1 Expression on Ewing's Sarcoma, Enhancing T Cell Cytotoxicity.

Journal: Cells
Published: September 30, 2021

Correction to: No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease.

Correction to: No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease.

Journal: Bone marrow transplantation
Published: August 10, 2021

Ewing Sarcoma-Derived Extracellular Vesicles Impair Dendritic Cell Maturation and Function.

Ewing Sarcoma-Derived Extracellular Vesicles Impair Dendritic Cell Maturation and Function.

Journal: Cells
Published: July 05, 2021

Targeting the Retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus.

Targeting the Retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus.

Journal: Nature communications
Published: May 28, 2021
Showing 1-12 of 19

Last Updated: 09/26/2026